Loading clinical trials...
Loading clinical trials...
Feasibility and Safety of Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors
Conditions
Interventions
Autologous aPD-L1 armored anti-CD22 CAR T cells
Locations
1
China
Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Start Date
August 1, 2020
Primary Completion Date
August 1, 2023
Completion Date
August 1, 2025
Last Updated
May 27, 2021
NCT06066138
NCT05039801
NCT04704661
NCT06625775
NCT07479732
NCT05223608
Lead Sponsor
Hebei Senlang Biotechnology Inc., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions